



Syncom Formulations (India) Limited

A WHO-GMP & ISO 9001-2000 Certified Company

CIN No.: L24239MH1988PLC047759

SYNCOM/SE/2023-24

14th February, 2024

Online filing at: www.listing.bseindia.com and
<https://neaps.nseindia.com/NEWLISTINGCORP/login.jsp>

To,
BSE Limited
Phiroze Jeejeebhoy Tower,
Dalal Street,
Mumbai (M.H.) 400 001
BSE CODE:524470

To,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (E),
Mumbai- 400051
NSE SYMBOL: SYNCOMF

Subject: Submission of the Un-Audited Standalone and Consolidated Financial Results along with Limited Review Report thereon for the Quarter and Nine Months ended on 31st December, 2023 as per Regulation 33(3)(d) of SEBI (LODR) Regulations, 2015.

Dear Sir/Ma'am,

This is in continuation of our letter no. **SYNCOM/SE/2023-24** dated 6th February, 2024 regarding intimation of Board meeting for consideration and approval of Standalone and Consolidated Un-Audited Financial Results for the Quarter and Nine Months ended on 31st December, 2023.

Pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015, we are pleased to the following:

1. Standalone and Consolidated Unaudited Financial Results of the Company for the Quarter and Nine Months ended on 31st December, 2023;
2. Standalone and Consolidated Limited Review Report by the Statutory Auditors of the company for the Quarter and Nine Months ended on 31st December, 2023.

which was considered and approved by the Board at their 5/2023-24 Meeting held on Wednesday, the 14th February, 2024.

The meeting of the board of directors was commenced at 11:00 AM and concluded at 05:20.PM.

We are also in process to file the aforesaid financial results in XBRL format within the stipulated time and same shall also be hosted at the website of the company www.sfil.in.

The Financial Results will also be published in widely circulated English & Marathi (Vernacular) newspaper in the prescribed format for that purpose.

You are requested to take on record the above said Standalone and Consolidated Un-Audited Financial Results along with Limited Review Report for your reference and record.

Thanking You,

Yours Faithfully,

For, SYNCOM FORMULATIONS (INDIA) LIMITED

**CS VAISHALI AGRAWAL
COMPANY SECRETARY &
COMPLIANCE OFFICER**

Encl: Standalone and Consolidated Un-Audited Financial Results and Limited Review Report.

Bringing a smile on every face...

Regd. Off. : 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (East), MUMBAI-400 093, INDIA, Tel.: 91-022-30887744-54, Fax: 91-022-30887755, Email: sfil87@syncomformulations.com

Works : 256-257, Sector-I, PITHAMPUR, Dist.-Dhar, M.P. - 454 775, INDIA, Tel.: 91-07292-403122, 407039, Fax: 91-07292-253404, Email: assistant2@sfil.in

Corp. Off. : 207, Saket Nagar, Near Saket Club, INDORE - 452 018, INDIA, Tel. : 91-0731-2700458, Email : finance@sfil.in

Website : <http://www.sfil.in>

Limited Review Report on Un-audited Standalone Financial Results for the Quarter & Ninth Month ended 31st December, 2023 pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015

To,
The Board of Directors
SYNCOM FORMULATIONS (INDIA) LIMITED
Indore (M.P.)

We have reviewed the accompanying statement of Standalone Unaudited Financial Results of **SYNCOM FORMULATIONS (INDIA) LIMITED ("the Company")**, for the period ended December, 31, 2023 ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (LODR) Regulations, 2015, as amended including relevant circular issued by the SEBI from time to time.

This statement which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 Interim Financial Reporting ("IND AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other Accounting principles generally accepted in India and in compliance with the Regulation 33 of the SEBI (LODR) Regulations, 2015, as amended, including relevant circulars issued by the SEBI from time to time. Our responsibility is to issue a report on these Financial Statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "*Review of Interim Financial Information performed by the Independent Auditor of the Entity*", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Accounting Standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Indore
Date: 14th February, 2024

For, Sanjay Mehta & Associates
Chartered Accountants
FRN: 011524C


CA Manish Mittal
(Partner)
M. No. 079452
UDIN: 24079452BJZYSX8939





SYNCOM FORMULATIONS (INDIA) LIMITED

Regd.Off :- 7,Niraj Industrial Estate,Off Mahakali Caves Road,Andheri (E) Mumbai-400093

Works:- 256-257, Sector - 1, Pithampur, Dist: Dhar-454775

E Mail:- finance@sfil.in, Website:- www.sfil.in, CIN :- L24239MH1988PLC047759


STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER/NINE MONTHS ENDED 31ST DECEMBER, 2023


Rs. In Lacs except EPS

S. No.	Particulars	Quarter Ended			Nine months		Year Ended
		31-12-2023	30-09-2023	31-12-2022	31-12-2023	31-12-2022	31-03-2023
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue from Operations	6334.22	6238.68	5738.29	18509.33	16327.47	22464.39
2	Other Income	434.89	400.35	197.85	1022.98	783.01	1460.95
3	Total Income (1 + 2)	6769.11	6639.03	5936.14	19532.31	17110.48	23925.34
4	EXPENSES						
	(a) Cost of materials consumed	3774.65	3325.08	2199.90	9365.04	7391.22	9946.06
	(b) Purchases of Stock-in-Trade	398.25	819.89	1094.05	2132.22	2939.98	4261.14
	(c) Changes in inventories of finished goods, Stock-in- Trade and work-in-progress	(279.99)	(308.60)	183.32	(198.06)	101.52	5.03
	(d) Employee benefits expense	973.63	900.10	725.67	2636.54	1866.79	2586.56
	(e) Finance costs	108.16	107.57	71.70	327.90	183.83	313.02
	(f) Depreciation and amortization expense	144.58	87.88	120.15	342.46	337.15	453.93
	(g) Other expenses	787.71	893.03	944.79	2668.67	2660.42	3704.28
	Total expenses (4)	5906.99	5824.95	5339.58	17274.77	15480.91	21270.02
5	Profit/(loss) before exceptional items and tax (3- 4)	862.12	814.08	596.56	2257.54	1629.57	2655.32
6	Exceptional Items	(2.39)	0.00	0.00	(2.39)	0.00	1.33
7	Profit/(loss) before tax (5 - 6)	859.73	814.08	596.56	2255.15	1629.57	2656.65
8	Tax expense:						
	(1) Current tax	207.81	148.41	161.00	516.52	406.00	664.84
	(2) Deferred tax	9.85	45.12	21.05	51.16	63.15	(15.26)
9	Profit (Loss) for the period from continuing operations (7-8)	642.07	620.55	414.51	1687.47	1160.42	2007.07
10	Profit/(loss) from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
11	Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
12	Profit/(loss) from Discontinued operations (after tax) (10-11)	0.00	0.00	0.00	0.00	0.00	0.00
13	Profit/(loss) for the period (9 + 12)	642.07	620.55	414.51	1687.47	1160.42	2007.07
14	Other Comprehensive Income						
	A(i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	B (i) Items that will be reclassified to profit or loss	185.71	124.34	111.57	516.82	147.51	196.36
	(ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
15	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (Loss) and Other Comprehensive Income for the period)	827.78	744.89	526.08	2204.29	1307.93	2203.43
16	Paid up Share Capital of the Company (Face Value 1/-)	9400.00	9400.00	9400.00	9400.00	9400.00	9400.00
17	Reserves excluding revaluation reserves	0.00	0.00	0.00	0.00	0.00	16201.47
18	Earnings per equity share (for continuing operation):						
	(1) Basic	0.09	0.08	0.06	0.23	0.14	0.24
	(2) Diluted	0.09	0.08	0.06	0.23	0.14	0.24
19	Earnings per equity share (for discontinued operation):						
	(1) Basic	0.00	0.00	0.00	0.00	0.00	0.00
	(2) Diluted	0.00	0.00	0.00	0.00	0.00	0.00
20	Earnings per equity share (for discontinued & continuing operations)						
	(1) Basic	0.09	0.08	0.06	0.23	0.14	0.24
	(2) Diluted	0.09	0.08	0.06	0.23	0.14	0.24

Place: Indore
Date: 14/02/2024

For, Syncom Formulations (India) Limited




Kedarmal Shankarlal Bankda
 Chairman & Wholetime Director
 DIN: 00023050



SYNCOM FORMULATIONS (INDIA) LIMITED

Regd.Off :- 7,Niraj Industrial Estate,Off Mahakali Caves Road,Andheri (E) Mumbai-400093

Works:- 256-257, Sector - 1, Pithampur, Dist: Dhar-454775

E Mail:- finance@sfil.in, Website:- www.sfil.in, CIN :- L24239MH1988PLC047759

STANDALONE STATEMENT OF SEGMENT WISE REVENUE, RESULTS ALONG WITH QUARTERLY /NINE MONTHS ENDED 31.12.23 UNAUDITED RESULTS


		Rs. In Lacs					
S. No.	Particulars	Quarter Ended			NINE MONTHS		Previous Year Ended
		31-12-2023	30-09-2023	31-12-2022	31-12-2023	31-12-2022	31-03-2023
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Segment Revenue						
	a) Pharmaceuticals Drugs & Formulations	6554.80	6255.88	4615.43	18370.09	15105.62	21037.66
	b) Trading of Commodities	114.39	286.04	1237.55	857.41	1749.39	2552.40
	c) Renting of Property	99.92	97.11	83.16	304.81	255.47	335.28
	Total Segment Revenue	6769.11	6639.03	5936.14	19532.31	17110.48	23925.34
	Less: Inter Segment Revenue	0.00	0.00	0.00	0.00	0.00	0.00
	Total Income	6769.11	6639.03	5936.14	19532.31	17110.48	23925.34
2	Segment Results Profit(+)/Loss(-) before tax and interest from each segment						
	a) Pharmaceuticals Drugs & Formulations	873.62	823.70	583.94	2293.30	1538.75	2620.14
	b) Trading of Commodities	-1.11	5.38	1.16	-1.43	19.18	32.43
	c) Renting of Property	95.38	92.57	83.16	291.18	255.47	317.10
	Total Profit before tax and Interest	967.89	921.65	668.26	2583.05	1813.40	2969.67
	Less: i) Interest	108.16	107.57	71.70	327.90	183.83	313.02
	ii) Other Un-allocable Expenditure	0.00	0.00	0.00	0.00	0.00	0.00
	Profit before tax	859.73	814.08	596.56	2255.15	1629.57	2656.65
3	(Segment Asset-Segment Liabilities)						
	Segment Asset						
	a) Pharmaceuticals Drugs & Formulations	36167.12	34624.25	33163.26	36167.12	33163.26	32002.05
	b) Trading of Commodities	41.27	1063.79	0.00	41.27	0.00	958.89
	c) Renting of Property	4740.64	4733.45	4733.45	4740.64	4733.45	4733.45
	Total Segment Asset	40949.03	40421.49	37896.71	40949.03	37896.71	37694.39
	Un-allocable Assets						
	Net Segment Asset	40949.03	40421.49	37896.71	40949.03	37896.71	37694.39
	Segment Liabilities						
	a) Pharmaceuticals Drugs & Formulations	12936.79	13155.03	13032.44	12936.79	13032.44	11749.56
	b) Trading of Commodities	52.11	131.38	0.00	52.11	0.00	179.91
	c) Renting of Property	163.91	163.44	157.79	163.91	157.79	163.44
	Total Segment Liabilities	13152.81	13449.85	13190.23	13152.81	13190.23	12092.91
	Un-allocable Liabilities	0.00	0.00	0.00	0.00	0.00	0.00
	Net Segment Liabilities	13152.81	13449.85	13190.23	13152.81	13190.23	12092.91

Notes:-

- The above results were reviewed by the Audit Committee and approved by the Board at its meeting held on 14/02/2024.
- These above results have been prepared in compliance with the Indian Accounting Standard (referred to as "Ind AS") as notified prescribed under Section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules 2015 as amended from time to time.
- The company is operating in 3 segments i.e. (a) Pharmaceuticals Drugs & Formulations (b) Trading of Commodities (c) Renting of Property, particulars of segment wise results are given as required.
- As required under Regulation 33 of SEBI (LODR) Regulations, 2015 the limited review by the Statutory Auditors have been completed for the quarter/nine months ended on 31st December, 2023. The report does not have any impact on the above results and notes which needs explanation.
- Previous period figures have been regrouped/reclassified wherever necessary to confirm to this period classification.
- The company has generated (From FY-2020-21 to FY-2022-23) Rs. 1035.76 Lakhs being the upfront amount and Rs. 2995.74 Lakhs by conversion of 15,93,47,820 warrants to 15,93,47,820 equity shares of Rs. 1/- each issued at a premium of Rs. 1.53 per share aggregating Rs. 4031.50 Lakhs. Out of which the company has already utilized the amount of Rs. 3994.16 Lakhs (Including capital work in progress), Remaining unutilized amount of Rs. 37.34 Lakhs will be used in the subsequent period. There is no deviation in the project till 31st Dec 2023 and necessary report towards as required under regulation 32 being filed to the BSE Ltd. Separately

Place: Indore

Date: 14/02/2024



For, Syncom Formulations (India) Limited

Kedarmal Shankarlal Bankda
Chairman & Wholtime Director

DIN: 00023050

Limited Review Report on Un-audited Consolidated Financial Results for the Quarter and Nine Months ended 31st December, 2023 pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015

To,
The Board of Directors
SYNCOM FORMULATIONS (INDIA) LIMITED
Indore (M.P.)

1. We have reviewed the accompanying statement of Consolidated Unaudited Financial Results of **SYNCOM FORMULATIONS (INDIA) LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the period ended December, 31, 2023 ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (LODR) Regulations, 2015, as amended including relevant circular issued by the SEBI from time to time.
2. This statement which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 Interim Financial Reporting ("IND AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other Accounting principles generally accepted in India and in compliance with the Regulation 33 of the SEBI (LODR) Regulations, 2015, as amended, including relevant circulars issued by the SEBI from time to time. Our responsibility is to issue a report on these Financial Statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "*Review of Interim Financial Information performed by the Independent Auditor of the Entity*", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. The Statement includes the results of the following entity:


S. No.	Name of the Company	Relationship with the Holding Company
1.	Sante Biotech Pvt. Ltd.	Wholly Owned Subsidiary
2.	Synmex Pharma Pvt. Ltd.	Wholly Owned Subsidiary
3.	Vincit Biotech International Pvt. Ltd.	Wholly Owned Subsidiary



5. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Accounting Standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, Sanjay Mehta & Associates
Chartered Accountants
FRN: 011524C

Place: Indore
Date: 14th February, 2024



CA Manish Mittal
(Partner)

M. No. 079452

UDIN: 24079452BJZYSY6937





SYNCOM FORMULATIONS (INDIA) LIMITED

Regd. Off :- 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (E) Mumbai-400093

Works:- 256-257, Sector - 1, Pithampur, Dist: Dhar-454775

E Mail:- finance@sfil.in, Website:- www.sfil.in, CIN :- L24239MH1988PLC047759

CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER/NINE MONTHS ENDED 31ST DECEMBER, 2023

Rs. In Lacs except EPS

S. No.	Particulars	Quarter Ended			Nine months		Year Ended
		31-12-2023	30-09-2023	31-12-2022	31-12-2023	31-12-2022	31-03-2023
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue from Operations	6513.95	6383.89	5738.29	18881.42	16327.47	22425.42
2	Other Income	455.54	399.74	197.85	1042.75	783.01	1459.99
3	Total Income (1 + 2)	6969.49	6783.63	5936.14	19924.17	17110.48	23885.41
4	EXPENSES						
	(a) Cost of materials consumed	3774.65	3325.08	2199.90	9365.04	7391.22	9946.06
	(b) Purchases of Stock-in-Trade	450.11	837.11	1094.05	2208.64	2939.98	4261.14
	(c) Changes in inventories of finished goods, Stock-in- Trade and work-in-progress	(271.89)	(251.75)	183.32	(155.42)	101.52	(37.61)
	(d) Employee benefits expense	973.63	900.10	725.67	2636.54	1866.79	2586.56
	(e) Finance costs	108.16	107.57	71.70	327.90	183.83	313.10
	(f) Depreciation and amortization expense	144.58	87.88	120.15	342.46	337.15	453.93
	(g) Other expenses	851.74	932.73	944.82	2804.32	2661.13	3706.30
	Total expenses (4)	6030.98	5938.72	5339.61	17529.48	15481.62	21229.48
5	Profit/(loss) before exceptional items and tax (3- 4)	938.51	844.91	596.54	2394.69	1628.86	2655.93
6	Exceptional Items	(2.39)	0.00	0.00	(2.39)	0.00	1.33
7	Profit/(loss) before tax (5 - 6)	936.12	844.91	596.54	2392.30	1628.86	2657.26
8	Tax expense:						
	(1) Current tax	226.10	148.62	161.00	550.17	406.00	665.45
	(2) Deferred tax	9.85	45.12	21.05	51.16	63.15	(15.26)
9	Profit (Loss) for the period from continuing operations (7-8)	700.17	651.17	414.49	1790.97	1159.71	2007.07
10	Profit/(loss) from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
11	Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
12	Profit/(loss) from Discontinued operations (after tax) (10-11)	0.00	0.00	0.00	0.00	0.00	0.00
13	Profit/(loss) for the period (9 + 12)	700.17	651.17	414.49	1790.97	1159.71	2007.07
14	Other Comprehensive Income						
	A(i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	B (i) Items that will be reclassified to profit or loss	185.71	124.34	111.57	516.82	147.51	196.36
	(ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
15	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (Loss) and Other Comprehensive Income for the period)	885.88	775.51	526.06	2307.79	1307.22	2203.43
16	Paid up Share Capital of the Company (Face Value 1/-)	9400.00	9400.00	9400.00	9400.00	9400.00	9400.00
17	Reserves excluding revaluation reserves	0.00	0.00	0.00	0.00	0.00	16201.47
18	Earnings per equity share (for continuing operation):						
	(1) Basic	0.09	0.08	0.06	0.25	0.14	0.24
	(2) Diluted	0.09	0.08	0.06	0.25	0.14	0.24
19	Earnings per equity share (for discontinued operation):						
	(1) Basic	0.00	0.00	0.00	0.00	0.00	0.00
	(2) Diluted	0.00	0.00	0.00	0.00	0.00	0.00
20	Earnings per equity share (for discontinued & continuing operations)						
	(1) Basic	0.09	0.08	0.06	0.25	0.14	0.24
	(2) Diluted	0.09	0.08	0.06	0.25	0.14	0.24

Place: Indore

Date: 14/02/2024



For, Syncom Formulations (India) Limited

Kedarnal Shankarlal Bankda
Chairman & Wholetime Director

DIN: 00023050

**SYNCOM FORMULATIONS (INDIA) LIMITED**

Regd.Off :- 7,Niraj Industrial Estate,Off Mahakali Caves Road,Andheri (E) Mumbai-400093

Works:- 256-257, Sector - 1, Pithampur, Dist: Dhar-454775

E Mail:- finance@sfil.in, Website:- www.sfil.in, CIN :- L24239MH1988PLC047759

CONSOLIDATED STATEMENT OF SEGMENT WISE REVENUE, RESULTS ALONG WITH QUARTERLY/NINE MONTHS ENDED 31/12/2023 UNAUDITED RESULTS


S. No.	Particulars	Quarter Ended			Nine Months		Rs. In Lacs
		31-12-2023	30-09-2023	31-12-2022	31-12-2023	31-12-2022	Year Ended
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Segment Revenue						
	a) Pharmaceuticals Drugs & Formulations	6755.87	6401.08	4615.43	18763.54	15105.62	20997.73
	b) Trading of Commodities	114.39	286.04	1237.55	857.41	1749.39	2552.40
	c) Renting of Property	99.23	96.51	83.16	303.22	255.47	335.28
	Total Segment Revenue	6969.49	6783.63	5936.14	19924.17	17110.48	23885.41
	Less: Inter Segment Revenue	0.00	0.00	0.00	0.00	0.00	0.00
	Total Income	6969.49	6783.63	5936.14	19924.17	17110.48	23885.41
2	Segment Results Profit(+)/Loss(-) before tax and interest from each segment						
	a) Pharmaceuticals Drugs & Formulations	950.71	855.13	583.92	2432.05	1538.04	2620.83
	b) Trading of Commodities	-1.11	5.38	1.16	-1.43	19.18	32.43
	c) Renting of Property	94.68	91.97	83.16	289.58	255.47	317.10
	Total Profit before tax and Interest	1044.28	952.48	668.24	2720.21	1812.69	2970.36
	Less: i) Interest	108.16	107.57	71.70	327.90	183.83	313.10
	ii) Other Un-allocable Expenditure	0.00	0.00	0.00	0.00	0.00	0.00
	Profit before tax	936.12	844.91	596.54	2392.31	1628.86	2657.26
3	(Segment Asset-Segment Liabilities)						
	Segment Asset						
	a) Pharmaceuticals Drugs & Formulations	35680.64	34572.02	33163.26	35680.64	33163.26	32090.72
	b) Trading of Commodities	41.27	1063.79	0.00	41.27	0.00	958.89
	c) Renting of Property	4740.64	4733.45	4733.45	4740.64	4733.45	4733.45
	Total Segment Asset	40462.55	40369.26	37896.71	40462.55	37896.71	37783.06
	Un-allocable Assets						
	Net Segment Asset	40462.55	40369.26	37896.71	40462.55	37896.71	37783.06
	Segment Liabilities						
	a) Pharmaceuticals Drugs & Formulations	12346.75	13057.38	13032.44	12346.75	13032.44	11838.21
	b) Trading of Commodities	52.11	131.38	0.00	52.11	0.00	179.91
	c) Renting of Property	163.91	163.44	157.79	163.91	157.79	163.44
	Total Segment Liabilities	12562.77	13352.20	13190.23	12562.77	13190.23	12181.56
	Un-allocable Liabilities	0.00	0.00	0.00	0.00	0.00	0.00
	Net Segment Liabilities	12562.77	13352.20	13190.23	12562.77	13190.23	12181.56

Notes:-

- The above results were reviewed by the Audit Committee and approved by the Board at its meeting held on 14/02/2024
- These above results have been prepared in compliance with the Indian Accounting Standard (referred to as "Ind AS") as notified prescribed under Section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules 2015 as amended from time to time.
- The company is operating in 3 segments i.e. (a) Pharmaceuticals Drugs & Formulations (b) Trading of Commodities (c) Renting of Property, particulars of segment wise results are given as required.
- As required under Regulation 33 of SEBI (LODR) Regulations, 2015 the limited review by the Statutory Auditors have been completed for the quarter/nine months ended on 31st December, 2023. The report does not have any impact on the above results and notes which needs explanation.
- Previous period figures have been regrouped/reclassified wherever necessary to confirm to this period classification.
- The company has generated (From FY-2020-21 to 2022-23) Rs. 1035.76 Lakhs being the upfront amount and Rs. 2995.74 Lakhs by conversion of 15,93,47,820 warrants to 15,93,47,820 equity shares of Rs. 1/- each issued at a premium of Rs. 1.53 per share aggregating Rs. 4031.50 Lakhs. Out of which the company has already utilized the amount of Rs. 3994.16 Lakhs (Including capital work in progress). Remaining unutilized amount of Rs. 37.34 Lakhs will be used in the subsequent period. There is no deviation in the project till 31st Dec 2023 and necessary report towards as required under regulation 32 being filed to the BSE Ltd. Separately

Place: Indore

Date: 14/02/2024



For, Syncom Formulations (India) Limited

Kedarnat Shankarlal Bankda
Chairman & Wholetime Director
DIN: 00023050